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e.2013.03Abstract Aim: To study the relationship between serum DNA and breast cancer proliferative
activity, then compare the diagnostic and prognostic values of serum DNA, TPS and CEA.
Subjects and methods: A total of 100 breast cancer patients before surgery and 50 apparently
healthy controls were analyzed for serum DNA, TPS and CEA.
Results: Serum DNA levels were nonsigniﬁcantly correlated with serum TPS levels. Serum DNA,
TPS and CEA levels were signiﬁcantly higher in patients than controls. Using ROC curve analysis,
serum TPS and DNA had the highest AUC compared to serum CEA. Neither serum TPS, DNA
nor CEA correlated with breast cancer clinicopathological data. Only serum CEA was signiﬁcantly
correlated with patients’ disease-free survival.
Conclusion: Neither Breast cancer mass nor proliferative activity is the source of serum free DNA.
Serum TPS is superior to DNA and CEA as a diagnostic marker for breast cancer. Only preoper-
ative serum CEA has a prognostic role in predicting relapse of breast cancer patients, but not serum
TPS or DNA.
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Several studies reported increased levels of free DNA in the
serum of patients with various types of cancers including
breast cancer.1 However, the mechanism by which cell-free
DNA is released into the circulation remains unknown. Some
studies suggested that the tumor itself may be the source of free
DNA.2 Other studies indicated that cell death by apoptosis or
necrosis may play a role in this phenomenon.3 It was reported
that tumor cell proliferative activity but not apoptosis may be
the source of free DNA.4lexandria University Faculty of Medicine.
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to human cytokeratin 18, which is an essential part of the pro-
tein cytoskeleton of epithelial cells.5 As opposed to CA 15-3,
which serum concentration provides data about tumor mass,
serum TPS levels indicate proliferative activity of malignant
tissue even if the mass is small.6 Elevated concentrations of
TPS have been detected in association with a wide variety of
malignancies, including breast cancer.7
Serum tumor markers have proved to be valuable and con-
venient for the detection of various primary and recurrent car-
cinomas. However, due to their low sensitivity and speciﬁcity,
markers such as carcinoembryonic antigen (CEA) have little
practical use in the early detection of patients with breast
cancer.8
In terms of free DNA quantiﬁcation, existing studies vary
with regard to the techniques used, the standardization and
analysis procedures.9 For example, in one study, the mean free
DNA concentration in lung cancer patients was 8-fold higher
than in controls10 but it was 13-fold lower than the concentra-
tions reported previously by the same authors.11 This differ-
ence was because the PCR method used in the second report
measured only ampliﬁable DNA,11 whereas the method used
in the original report (spectrophotometer) could detect all
DNA fragments.10 In the present study, we quantiﬁed the
whole amount of free DNA present in serum by spectropho-
tometry at 260 nm depending on the idea that a DNAmolecule
contains a system of conjugated double bonds which absorb
the UV light maximally at 260 nm.
The aim of the present study was to investigate whether or
not a relationship exists between the level of serum DNA and
TPS as a tumor proliferative index, then compare the diagnos-
tic and prognostic values of serum DNA, TPS and CEA in
breast cancer patients.
2. Subjects and methods
One hundred and ﬁfty females were included in this study
within the period from January 2007 to May 2008. They were
divided into two groups: group I included 100 breast cancer
patients with invasive ductal carcinoma of clinical stages II
and III,12 recently detected, with no surgical interference, not
given chemotherapy; mean age: 48.36 ± 9.75 years. Patients
were recruited from the Department of Cancer Management
and Research of the Medical Research Institute, Alexandria
University. Group II included 50 apparently healthy controls
of matched age 47.45 ± 10.5, menstrual and socioeconomic
status.
After having approval from the ethics committee, Medical
Research Institute, Alexandria University, Egypt, signed in-
formed consents were obtained from all subjects who agreed
to participate in this study. A full history was recorded and
each patient underwent: a thorough clinical examination, rou-
tine laboratory investigations, mammography of both breasts,
radiological investigations including X-ray of chest, ultraso-
nography of abdomen and liver, computed tomography (CT)
scan of chest and abdomen and bone scan when needed, and
ﬁne-needle aspiration cytology (FNAC) of breast mass to
establish the pathological diagnosis of the patients.
The clinicopathologic data were obtained from patients’
pathology reports. The collected data included: tumor size, tu-
mor pathological grade, axillary lymph node involvement,vascular invasion, estrogen receptor (ER) and progesterone
receptor (PR) status and HER-2expression. For each patient,
clinical stage was determined by the oncologist according to
the tumor-node-metastasis (TNM) classiﬁcation system.13
All 100 breast cancer patients underwent modiﬁed radical
mastectomy, then received adjuvant combination chemother-
apy (5-ﬂuorouracil, adriamycin and cyclophosphamide
[FAC])14 for six cycles. The patients were re-evaluated after
three and six cycles of chemotherapy to estimate clinical re-
sponse. They were followed up for 50 months until June
2012 for assessment of disease-free survival.
2.1. Laboratory investigations
Five milliliter venous blood samples were collected from the
controls and patients before surgery. Immediately after with-
drawing, blood samples were allowed to coagulate and then
centrifuged for 20 min at 3500 rpm at 4 C. The separated ser-
um samples were aliquoted and stored frozen at 80 C. After
thawing, each serum sample was assayed once. Determination
of serum concentrations of DNA, TPS and CEA was carried
out at the radioisotopes laboratory of Radiation Sciences
Department, Medical Research Institute, Alexandria
University.
2.2. Puriﬁcation of serum free DNA
The obtained serum was used to extract DNA using a ready-
for use QIAamp DNA mini kit (Qiagen, Hilden, Germany).
Brieﬂy, serum was mixed with a protein kinase and a lysis buf-
fer and incubated at 56 C for 20 min in a microcentrifuge
tube. Ethanol was added and the reaction mixture was applied
to the QIAamp mini spin column. After washing, the column
was eluted with the elution buffer.
2.3. Determination of serum free DNA concentration and purity
Serum free DNA concentration was measured at the wave-
length of 260 nm by Nanodrop 2000/2000C spectrophotome-
ter (thermo ﬁsher Scientiﬁc Inc, Nanodrop Technologies,
Wilmington, NC, USA). By using a standard curve, it is pos-
sible to calculate the absolute concentration of target DNA in
a sample. In this study, we generated a standard curve using
serial dilutions of known concentrations of DNA (500, 250,
100, 80, 40, 20, 10, 5, 0 ng/ll). Also, the purity was estimated
from the ratio of absorbance at 260 nm and 280 nm (A260/
A280). A ratio of 1.8 (1.7–1.9) is generally accepted for pure
DNA.
2.4. Determination of serum CEA concentrations
The level of serum CEA was determined using a ready-for-use
Immunoradiometric assay (IRMA) kit (Siemens, USA)
according to the producer’s protocol. Brieﬂy, serum was added
to a plastic tube coated with the capture antibody. CEA assay
buffer was added to the tubes which were shaken for 1 h at
room temperature. The tubes were decanted and washed with
the wash buffer. I125- CEA antibody was added to all tubes
which were shaken for 1 h at room temperature. The tubes
were decanted, washed with the wash buffer and counted for
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Figure 1 ROC curve analysis of serum DNA, TPS and CEA for
prediction of breast cancer.
Breast cancer proliferative activity: Is it the source of serum free DNA? 3391 min in a gamma counter (Perkin Elmer, Finland). Computer
assisted data reduction was used to simplify the calculations.
The ﬁve- parameter logistic function curve was used to calcu-
late CEA level in each serum sample.
2.5. Determination of serum tissue polypeptide speciﬁc antigen
(TPS) concentrations
Serum TPS level was determined using a ready-for-use ELISA
kit (DRG diagnostics, Germany) according to the manufac-
turer’s protocol. Brieﬂy, serum was added into each well, fol-
lowed by HRP-conjugated Anti-TPS solution. Wells were
shaken on a rack shaker (600 rpm) for 2 h at room tempera-
ture. Wells were decanted and washed with diluted wash solu-
tion. Tetramethyl-benzidine (TMB) substrate solution was
added per well and incubated in the dark for 20 min. Stop
solution was added per well and the wells were mixed well.
Absorbance of every well was read at 450 nm. A standard
curve was constructed from which the concentration of TPS
in each serum sample was determined. The assay sensitivity
was 6 U/L.
2.6. Statistical analysis
Statistical analysis was performed using the PASW 18 software
package. The distribution of quantitative variables was tested
for normality using Kolmogorov–Smirnov test, Shapiro–Wilk
test. The data were abnormally distributed, so non-parametric
tests were used. Non-parametric Spearman’s test was used to
investigate correlations between different parameters. The
Mann–Whitney U-test was used for studying differences be-
tween the patient and control groups. The Receiver Operating
Characteristic (ROC) curve analysis was used to compare the
diagnostic accuracies of the studied parameter. Univariate sur-
vival analysis of the studied parameters was assessed using the
Kaplan–Meier method. Statistical differences between survival
curves were evaluated using the log-rank test. p< 0.05 was
considered as signiﬁcant.
3. Results
3.1. Correlation between serum DNA levels and breast cancer
proliferative activity
In the present study, serum TPS was considered as a tumor
proliferative index. A non-signiﬁcant correlation (r= 0.177,
p= 0.116) was found between serum DNA and TPS.
3.2. Median (range) of serum DNA, CEA and TPS levels in the
breast cancer patients and apparently healthy controls
In women with breast cancer, serum concentrations of DNA
(83.10 (42–221) ng/ll), CEA (4.0 (1.0–24.0 ng/ml) and TPS
(144 (60–243) U/L) were signiﬁcantly higher than those in con-
trol women (DNA: 49.00 (33–69) ng/lL, CEA: 3.5(0–11) ng/ml
and TPS: 34 (10–175) U/L), (P= 0.000, P= 0. 013 and
P= 0.000 respectively).
Comparison between serum DNA, CEA and TPS as diag-
nostic markers in breast cancer patients using the Receiver
Operating Characteristic (ROC) curve analysis was done.In the present study, the assayed serum parameters were of
diagnostic value in breast cancer patients. So, the ROC curves
of serum DNA and TPS were constructed to compare their
diagnostic value with that of CEA, in such a way that the higher
area under the curve (AUC) corresponds to a better diagnostic
test, Fig. 1. To obtain the optimal cut off value for each param-
eter in predicting breast cancer, we chose the point on the ROC
curve which represented the largest sum of sensitivity and spec-
iﬁcity. As shown in Fig. 1 and Table 1, the AUC for serum TPS
was 93.6% suggesting a strong discrimination power and nom-
inates serum TPS as a diagnostic test with an excellent accuracy
compared with serum DNA which has an AUC of 92.9% and
serum CEA that has an AUC of 67.1% that is also a diagnostic
marker with poor diagnostic accuracy. The probability that a
female is affected by breast cancer when having positive serum
TPS, DNA and CEA results is 85%, 98.5% and 53.6%, respec-
tively. While the probability that a female is free from breast
cancer when having negative serum TPS, DNA and CEA re-
sults is 77.5%, 72.2% and 54.6%, respectively
3.3. The relationship between serum DNA, CEA and TPS levels
and clinicopathological data in breast cancer patients before
surgery
Neither serum TPS, DNA nor CEA levels showed a signiﬁcant
correlation with the clinicopathological data of breast cancer
patients
3.4. Relationship between preoperative serum DNA, CEA and
TPS levels and patients’ disease-free survival
Kaplan–Meier analysis and log-rank test revealed that serum
DNA and TPS did not correlate with disease-free survival
(p= 0.540, p= 0.602; respectively), while patients with ele-
vated levels of serum CEA (P4.88 ng/ml) had a signiﬁcant
shorter disease-free survival than those who had lower levels
of this biomarker (p= 0.037) as shown in Fig. 2 and Table 2.
4. Discussion
The origin of circulating DNA is not fully understood. Quali-
tative studies have shown that genetic alternations such as
Table 1 Cut-off values and corresponding sensitivity, speciﬁcity, PPV and NPV for serum DNA, TPS and CEA for prediction of
breast cancer.
Biomarker AUC (%) p-Value Cut-oﬀ values Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
TPS (U/L) 93.6 0.00* 71 94.3 81.1 85 77.5
DNA (ng/ll) 92.9 0.00* 65.7 77.1 97.3 98.5 72.2
CEA (ng/ml) 67.1 0.01* 4.88 48.6 85.9 53.6 54.6
AUC: Area under the curve.
PPV: Positive predictive value.
NPP: Negative predictive value.
* Statistically signiﬁcant at p< 0.05.
Figure 2 Kaplan–Meier disease-free survival curve for 100
breast cancer patients evaluated according to the levels of serum
CEA at diagnosis.
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circulating DNA, as well as in the matching tumor cells, sug-
gesting that part of the extra circulating DNA in cancer pa-
tients is attributed to DNA released from tumor cells.15–17
In the present study, the absence of correlation between ser-
um DNA and TPS indicated that the proliferative activity of
breast cancer cells is not the origin of serum free DNA. This
result is conﬁrming the results of Sozzi et al10 who suggested
that the mechanism of release of DNA into circulation is not
related to tumor cell proliferation.Table 2 Correlation between preoperative serum DNA, TPS and C
patients.
Cut oﬀ values Survival time
Mean ± SE
DNA concentration (ng/ll) 665.7 (Negative) 40.27 ± 2.94
>65.7 (Positive) 42.62 ± 1.25
TPS (U/L) 671 (Negative) 40 ± 3.30
>70 (Positive) 42.56 ± 1.23
CEA (ng/ml) <4.88 (Negative) 45.91 ± 1.25
P4.88 (Positive) 36.71 ± 3.53Also, in the present study, the absence of correlation be-
tween serum DNA and breast cancer clinicopathological data
indicates that the tumor mass is not the source of free serum
DNA. Our results are in agreement with those of Gal et al.18
who suggested that the mechanism of DNA release from tu-
mors is not related to any of the known commonly used major
prognostic factors and therefore might highlight different
pathways, such as apoptosis, necrosis, and hypoxia that would
need to be investigated. Gal et al.18 also stated that at least a
proportion of the excess serum DNA in patients with tumors
originates from a host response to the tumor (i.e. normal
rather than tumor DNA).
The results of the present study provide an evidence of in-
creased amounts of serum DNA, TPS and CEA in breast can-
cer patients than apparently healthy controls. This means that
serum DNA, TPS and CEA levels can be used as a tool to dis-
tinguish breast cancer patients from apparently healthy con-
trols. For TPS, our results are in agreement with the results
of Kassim et al.19 For DNA, our results conﬁrmed those of
Sozzi et al.,11 Gal et al.18 and Huang et al.1 For CEA, our re-
sults supported those of Samy et al.20
In the present study, to compare the accuracy of serum
DNA, TPS and CEA in predicting breast cancer, the ROC
curve was constructed which showed that serum TPS is supe-
rior to DNA and CEA for prediction of breast cancer. For
TPS, at a cut-off level 71 U/L, the sensitivity was 94.3% and
the speciﬁcity was 81.1%, with AUC 93.6%. These results
are close to those of Kassim et al.19 who reported that at a
cut-off 88 U/L, the sensitivity was 95%, and the speciﬁcity
was 75% with AUC of 91%. The greater cut-off value in
Kassim et al. study19 may be due to that their control group
was from patients with benign breast diseases instead of appar-
ently healthy controls. For serum DNA, at a cut-off concentra-
tion 65.7 ng/ll, the sensitivity was 77.1% and the speciﬁcity was
97.3%, with AUC 92.9%. Our results supported those found byEA levels and disease-free survival (months) among breast cancer
(months) 95% Conﬁdence interval P-value
Lower bound Upper bound
34.51 46.03 P= 0.540
40.16 45.07
33.53 46.47 P= 0.602
40.18 44.97
43.45 48.36 P= 0.037*
29.80 43.63
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221 ng/ml, the sensitivity was 70.8% and the speciﬁcity was
93.7%, with AUC 92%. For CEA, at a cut-off concentration
4.88 ng/ml, the sensitivity was 48.6% and the speciﬁcity was
85.9%, with AUC 67.1%. These results were in agreement
with those of Vizcarra et al.21 who reported that at cut-off level
5 ng/ml, the diagnostic sensitivity and speciﬁcity of CEA in
breast cancer were 44.4% and 95.5%, respectively.
The present study revealed that neither serum TPS nor
CEA correlated with breast cancer clinicopathological data.
Our results are compatible with the results reported by Hu
et al.22 regarding TPS and Zheng et al.23 regarding CEA.
The present study showed that neither serum DNA nor
TPS correlated with disease-free survival. For serum DNA,
our results supported those of Sozzi et al.11 and Beau-faller
et al.17 in lung cancer, but contradicted the results reported
by Silva et al.24 in breast cancer. The present study showed
that serum CEA correlated signiﬁcantly with breast cancer pa-
tients’ disease-free survival which supported the results re-
ported by Park et al.25
In conclusion, neither breast cancer mass nor proliferative
activity is the source of serum free DNA. Serum TPS is supe-
rior to DNA and CEA as diagnostic markers. Preoperative
CEA level has a prognostic role in predicting relapse of breast
cancer patients, but not serum TPS and DNA. Further studies
are needed to determine the exact mechanism of free DNA re-
lease into the circulation.
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